Identification

Name
Ardeparin
Accession Number
DB00407  (APRD00803)
Type
Small Molecule
Groups
Approved, Investigational, Withdrawn
Description

Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with an average molecular weight of 5500 to 6500. Normiflo was withdrawn from the US market in March 2000.

Synonyms
Not Available
International/Other Brands
Normiflo (Wyeth-Ayerst (United States))
Categories
UNII
VL0L558GCB
CAS number
9005-49-6
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

For prevention of deep vein thrombosis, which may result in pulmonary embolism, following knee surgery.

Structured Indications
Not Available
Pharmacodynamics

Ardeparin, an anticoagulant, is a fractionated heparin. It acts at multiple sites in the normal coagulation system to inhibit reactions that lead to the clotting of blood and the formation of fibrin clots both in vitro and in vivo.

Mechanism of action

Ardeparin binds to antithrombin III, accelerating its activity in inactivating factor Xa and thrombin, thereby inhibiting thrombosis. Ardeparin also binds to heparin cofactor II, inhibiting thrombin. Ardeparin does not effect prothrombin time (PT) assays and may prolong activated partial thromboplastin time (APTT). Ardeparin has double the anti-factor Xa activity versus anti-factor IIa activity, compared to unfractionated heparin which has approximately equal anti-factor Xa activity and anti-factor IIa activity.

TargetActionsOrganism
AAntithrombin-III
potentiator
Human
AHeparin cofactor 2
agonist
Human
Absorption

Well absorbed following subcutaneous administration, with a mean bioavailability of 92% (based on anti-factor Xa activity).

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Liver and the reticulo-endothelial system are the sites of biotransformation.

Route of elimination
Not Available
Half life

Elimination half-life for anti-factor Xa activity averages 3.3 hours following a single intravenous dose, while elimination half-life for anti-factor IIa activity averages 1.2 hours following a single intravenous dose.

Clearance
Not Available
Toxicity

Symptoms of overdose may include excessive bleeding and bruising.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Enoxaparin Action PathwayDrug action
Ardeparin Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may increase the anticoagulant activities of Ardeparin.Investigational
AbciximabAbciximab may increase the anticoagulant activities of Ardeparin.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Ardeparin.Approved, Investigational
AcemetacinThe risk or severity of bleeding can be increased when Ardeparin is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolArdeparin may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Ardeparin.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Ardeparin.Approved
AlclofenacAlclofenac may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
AliskirenArdeparin may increase the hyperkalemic activities of Aliskiren.Approved, Investigational
AllylestrenolThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Allylestrenol.Approved
AlminoprofenAlminoprofen may increase the anticoagulant activities of Ardeparin.Experimental
AloxiprinAloxiprin may increase the anticoagulant activities of Ardeparin.Experimental
AlprostadilAlprostadil may increase the anticoagulant activities of Ardeparin.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Ardeparin.Approved
AltrenogestThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Altrenogest.Vet Approved
AmilorideArdeparin may increase the hyperkalemic activities of Amiloride.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Ardeparin.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Ardeparin.Approved
AncrodArdeparin may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Ardeparin.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Ardeparin.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Ardeparin.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Ardeparin.Approved, Investigational
Antithrombin III humanArdeparin may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanApixaban may increase the anticoagulant activities of Ardeparin.Approved
ApocyninApocynin may increase the anticoagulant activities of Ardeparin.Investigational
ApremilastApremilast may increase the anticoagulant activities of Ardeparin.Approved, Investigational
AprotininThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Aprotinin.Approved, Investigational, Withdrawn
ArgatrobanArgatroban may increase the anticoagulant activities of Ardeparin.Approved, Investigational
AstaxanthinAstaxanthin may increase the anticoagulant activities of Ardeparin.Investigational
AzapropazoneAzapropazone may increase the anticoagulant activities of Ardeparin.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Ardeparin.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Ardeparin is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilArdeparin may increase the hyperkalemic activities of Azilsartan medoxomil.Approved, Investigational
BalsalazideBalsalazide may increase the anticoagulant activities of Ardeparin.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Ardeparin.Experimental
BecaplerminBecaplermin may increase the anticoagulant activities of Ardeparin.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Ardeparin.Approved, Investigational
BendazacBendazac may increase the anticoagulant activities of Ardeparin.Experimental
BenorilateBenorilate may increase the anticoagulant activities of Ardeparin.Experimental
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Ardeparin.Withdrawn
BenzydamineBenzydamine may increase the anticoagulant activities of Ardeparin.Approved
BeraprostBeraprost may increase the anticoagulant activities of Ardeparin.Investigational
BevoniumBevonium may increase the anticoagulant activities of Ardeparin.Experimental
BivalirudinBivalirudin may increase the anticoagulant activities of Ardeparin.Approved, Investigational
BrinaseBrinase may increase the anticoagulant activities of Ardeparin.Experimental
BromfenacBromfenac may increase the anticoagulant activities of Ardeparin.Approved
BucillamineBucillamine may increase the anticoagulant activities of Ardeparin.Investigational
BufexamacBufexamac may increase the anticoagulant activities of Ardeparin.Approved, Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Ardeparin.Experimental
BumadizoneBumadizone may increase the anticoagulant activities of Ardeparin.Experimental
ButylphthalideButylphthalide may increase the anticoagulant activities of Ardeparin.Investigational
CanagliflozinArdeparin may increase the hyperkalemic activities of Canagliflozin.Approved
CandesartanArdeparin may increase the hyperkalemic activities of Candesartan.Experimental
Candesartan cilexetilArdeparin may increase the hyperkalemic activities of Candesartan cilexetil.Approved
CangrelorCangrelor may increase the anticoagulant activities of Ardeparin.Approved
CaplacizumabCaplacizumab may increase the anticoagulant activities of Ardeparin.Investigational
Carbaspirin calciumCarbaspirin calcium may increase the anticoagulant activities of Ardeparin.Experimental, Investigational
CarprofenCarprofen may increase the anticoagulant activities of Ardeparin.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the anticoagulant activities of Ardeparin.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Ardeparin.Approved, Investigational
CertoparinArdeparin may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineChloroquine may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Vet Approved
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Ardeparin.Investigational, Withdrawn
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the anticoagulant activities of Ardeparin.Approved
CilostazolCilostazol may increase the anticoagulant activities of Ardeparin.Approved, Investigational
Citric AcidArdeparin may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Ardeparin.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Ardeparin.Approved
CloricromenCloricromen may increase the anticoagulant activities of Ardeparin.Experimental
ClorindioneClorindione may increase the anticoagulant activities of Ardeparin.Experimental
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Ardeparin is combined with Collagenase clostridium histolyticum.Approved, Investigational
Conjugated estrogensConjugated estrogens may decrease the anticoagulant activities of Ardeparin.Approved
CurcuminCurcumin may increase the anticoagulant activities of Ardeparin.Approved, Investigational
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Ardeparin.Approved
DaidzeinDaidzein may decrease the anticoagulant activities of Ardeparin.Experimental
DalteparinArdeparin may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidArdeparin may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanArdeparin may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Ardeparin.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Ardeparin is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Ardeparin.Approved, Investigational
DemegestoneThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Demegestone.Experimental
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Ardeparin is combined with Deoxycholic Acid.Approved
DersalazineDersalazine may increase the anticoagulant activities of Ardeparin.Investigational
DesirudinArdeparin may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Ardeparin.Investigational
DesogestrelThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Desogestrel.Approved
DextranArdeparin may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DiclofenacDiclofenac may increase the anticoagulant activities of Ardeparin.Approved, Vet Approved
DicoumarolDicoumarol may increase the anticoagulant activities of Ardeparin.Approved
DienestrolDienestrol may decrease the anticoagulant activities of Ardeparin.Approved, Investigational
DienogestThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Ardeparin.Approved, Investigational
DifenpiramideDifenpiramide may increase the anticoagulant activities of Ardeparin.Experimental
DiflunisalDiflunisal may increase the anticoagulant activities of Ardeparin.Approved, Investigational
DiphenadioneDiphenadione may increase the anticoagulant activities of Ardeparin.Experimental
DipyridamoleDipyridamole may increase the anticoagulant activities of Ardeparin.Approved
DitazoleDitazole may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Ardeparin.Withdrawn
DuvelisibDuvelisib may increase the anticoagulant activities of Ardeparin.Investigational
DydrogesteroneThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Dydrogesterone.Approved, Investigational, Withdrawn
E-6201E-6201 may increase the anticoagulant activities of Ardeparin.Investigational
Edetic AcidArdeparin may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Ardeparin.Approved
EnoxaparinArdeparin may increase the anticoagulant activities of Enoxaparin.Approved
EpimestrolEpimestrol may decrease the anticoagulant activities of Ardeparin.Experimental
EpinastineEpinastine may increase the anticoagulant activities of Ardeparin.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Ardeparin.Approved
EplerenoneArdeparin may increase the hyperkalemic activities of Eplerenone.Approved
EplivanserinEplivanserin may increase the anticoagulant activities of Ardeparin.Investigational
eplivanserineeplivanserine may increase the anticoagulant activities of Ardeparin.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Ardeparin.Approved
EprosartanArdeparin may increase the hyperkalemic activities of Eprosartan.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Ardeparin.Approved, Investigational
EquolEquol may decrease the anticoagulant activities of Ardeparin.Investigational
EstradiolEstradiol may decrease the anticoagulant activities of Ardeparin.Approved, Investigational, Vet Approved
Estradiol acetateEstradiol acetate may decrease the anticoagulant activities of Ardeparin.Approved, Investigational, Vet Approved
Estradiol cypionateEstradiol cypionate may decrease the anticoagulant activities of Ardeparin.Approved, Investigational, Vet Approved
Estradiol valerateEstradiol valerate may decrease the anticoagulant activities of Ardeparin.Approved, Investigational, Vet Approved
EstriolEstriol may decrease the anticoagulant activities of Ardeparin.Approved, Investigational, Vet Approved
Estrogens, esterifiedEstrogens, esterified may decrease the anticoagulant activities of Ardeparin.Approved
EstroneEstrone may decrease the anticoagulant activities of Ardeparin.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Ardeparin.Approved, Investigational
EthenzamideEthenzamide may increase the anticoagulant activities of Ardeparin.Experimental
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Ardeparin.Approved
Ethyl biscoumacetateArdeparin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthynodiolThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Ethynodiol.Experimental
EtodolacEtodolac may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Ardeparin.Approved, Investigational
EtonogestrelThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibEtoricoxib may increase the anticoagulant activities of Ardeparin.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Ardeparin.Investigational, Nutraceutical
ExisulindExisulind may increase the anticoagulant activities of Ardeparin.Investigational
FelbinacFelbinac may increase the anticoagulant activities of Ardeparin.Experimental
FenbufenFenbufen may increase the anticoagulant activities of Ardeparin.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Ardeparin.Approved
FentiazacFentiazac may increase the anticoagulant activities of Ardeparin.Experimental
FeprazoneFeprazone may increase the anticoagulant activities of Ardeparin.Experimental
Ferulic acidFerulic acid may increase the anticoagulant activities of Ardeparin.Experimental
FibrinolysinFibrinolysin may increase the anticoagulant activities of Ardeparin.Investigational
FimasartanArdeparin may increase the hyperkalemic activities of Fimasartan.Approved, Investigational
FloctafenineFloctafenine may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
FluindioneArdeparin may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlunixinFlunixin may increase the anticoagulant activities of Ardeparin.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the anticoagulant activities of Ardeparin.Experimental
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Ardeparin.Approved, Investigational
FondaparinuxArdeparin may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumArdeparin may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanArdeparin may increase the hyperkalemic activities of Forasartan.Experimental
GabexateArdeparin may increase the anticoagulant activities of Gabexate.Investigational
GenisteinGenistein may decrease the anticoagulant activities of Ardeparin.Investigational
GestodeneThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Gestodene.Approved, Investigational
GestonoroneThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Gestonorone.Experimental
GestrinoneThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Gestrinone.Approved
GuacetisalGuacetisal may increase the anticoagulant activities of Ardeparin.Experimental
HeminHemin may increase the anticoagulant activities of Ardeparin.Approved, Investigational
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the anticoagulant activities of Ardeparin.Experimental
HeparinArdeparin may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolHexestrol may decrease the anticoagulant activities of Ardeparin.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Ardeparin.Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Hydroxyprogesterone caproate.Approved, Investigational
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Ardeparin.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Ardeparin is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ardeparin.Approved
IbudilastIbudilast may increase the anticoagulant activities of Ardeparin.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Ardeparin.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Ardeparin.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Ardeparin.Approved, Investigational
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Nutraceutical
IdraparinuxArdeparin may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Ardeparin.Investigational
IloprostIloprost may increase the anticoagulant activities of Ardeparin.Approved, Investigational
Imidazole salicylateImidazole salicylate may increase the anticoagulant activities of Ardeparin.Experimental
IndobufenIndobufen may increase the anticoagulant activities of Ardeparin.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Ardeparin.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Ardeparin.Withdrawn
IrbesartanArdeparin may increase the hyperkalemic activities of Irbesartan.Approved, Investigational
IsoxicamIsoxicam may increase the anticoagulant activities of Ardeparin.Withdrawn
KebuzoneKebuzone may increase the anticoagulant activities of Ardeparin.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Ardeparin.Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Ardeparin.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Ardeparin.Approved
LeflunomideLeflunomide may increase the anticoagulant activities of Ardeparin.Approved, Investigational
LepirudinLepirudin may increase the anticoagulant activities of Ardeparin.Approved
LetaxabanArdeparin may increase the anticoagulant activities of Letaxaban.Investigational
LevonorgestrelThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Ardeparin.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Ardeparin.Experimental
LisofyllineLisofylline may increase the anticoagulant activities of Ardeparin.Investigational
LonazolacLonazolac may increase the anticoagulant activities of Ardeparin.Experimental
LornoxicamLornoxicam may increase the anticoagulant activities of Ardeparin.Approved, Investigational
LosartanArdeparin may increase the hyperkalemic activities of Losartan.Approved
LoxoprofenLoxoprofen may increase the anticoagulant activities of Ardeparin.Approved, Investigational
LumiracoxibLumiracoxib may increase the anticoagulant activities of Ardeparin.Approved, Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Ardeparin.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Ardeparin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Ardeparin.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Ardeparin.Approved
Megestrol acetateThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Megestrol acetate.Approved, Investigational, Vet Approved
MelagatranArdeparin may increase the anticoagulant activities of Melagatran.Experimental
MeloxicamMeloxicam may increase the anticoagulant activities of Ardeparin.Approved, Vet Approved
MesalazineMesalazine may increase the anticoagulant activities of Ardeparin.Approved
MestranolMestranol may decrease the anticoagulant activities of Ardeparin.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
MethallenestrilMethallenestril may decrease the anticoagulant activities of Ardeparin.Experimental
Methyl salicylateMethyl salicylate may increase the anticoagulant activities of Ardeparin.Approved, Vet Approved
MethylestrenoloneThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Methylestrenolone.Experimental
MilrinoneMilrinone may increase the anticoagulant activities of Ardeparin.Approved
MizoribineMizoribine may increase the anticoagulant activities of Ardeparin.Investigational
MofebutazoneMofebutazone may increase the anticoagulant activities of Ardeparin.Experimental
MoxestrolMoxestrol may decrease the anticoagulant activities of Ardeparin.Experimental
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Ardeparin.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Ardeparin.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Ardeparin.Approved
NadroparinArdeparin may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatNafamostat may increase the anticoagulant activities of Ardeparin.Approved, Investigational
NaftifineNaftifine may increase the anticoagulant activities of Ardeparin.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Ardeparin.Investigational
NaproxenNaproxen may increase the anticoagulant activities of Ardeparin.Approved, Vet Approved
NepafenacNepafenac may increase the anticoagulant activities of Ardeparin.Approved, Investigational
NifenazoneNifenazone may increase the anticoagulant activities of Ardeparin.Experimental
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Ardeparin.Approved
NimesulideNimesulide may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Ardeparin is combined with Nintedanib.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Ardeparin.Investigational
NomegestrolThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Norethisterone.Approved
NorgestrienoneThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Norgestrienone.Experimental
ObinutuzumabThe risk or severity of adverse effects can be increased when Ardeparin is combined with Obinutuzumab.Approved, Investigational
OlmesartanArdeparin may increase the hyperkalemic activities of Olmesartan.Approved, Investigational
OlopatadineOlopatadine may increase the anticoagulant activities of Ardeparin.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Ardeparin.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Ardeparin is combined with Omacetaxine mepesuccinate.Approved, Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Ardeparin.Approved, Nutraceutical
Omega-3-carboxylic acidsThe therapeutic efficacy of Ardeparin can be increased when used in combination with Omega-3-carboxylic acids.Approved, Investigational
OrgoteinOrgotein may increase the anticoagulant activities of Ardeparin.Vet Approved
OtamixabanArdeparin may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Ardeparin.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
OzagrelOzagrel may increase the anticoagulant activities of Ardeparin.Investigational
PaliferminThe serum concentration of Palifermin can be increased when it is combined with Ardeparin.Approved
ParecoxibParecoxib may increase the anticoagulant activities of Ardeparin.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Ardeparin.Approved, Investigational
ParthenolideParthenolide may increase the anticoagulant activities of Ardeparin.Approved, Investigational
Pentaerythritol TetranitrateArdeparin may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Ardeparin.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Ardeparin.Approved, Investigational
PhenindioneArdeparin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonArdeparin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Phenyl aminosalicylatePhenyl aminosalicylate may increase the anticoagulant activities of Ardeparin.Approved
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Ardeparin.Approved, Vet Approved
PicotamidePicotamide may increase the anticoagulant activities of Ardeparin.Experimental
PimecrolimusPimecrolimus may increase the anticoagulant activities of Ardeparin.Approved, Investigational
PirfenidonePirfenidone may increase the anticoagulant activities of Ardeparin.Approved, Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Ardeparin.Approved, Investigational
PirprofenPirprofen may increase the anticoagulant activities of Ardeparin.Experimental
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Ardeparin.Approved
PranoprofenPranoprofen may increase the anticoagulant activities of Ardeparin.Experimental, Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Ardeparin.Approved
ProgesteroneThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Progesterone.Approved, Vet Approved
ProglumetacinProglumetacin may increase the anticoagulant activities of Ardeparin.Experimental
PromegestoneThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Promegestone.Experimental
PromestrienePromestriene may decrease the anticoagulant activities of Ardeparin.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Ardeparin.Approved, Investigational
PropyphenazonePropyphenazone may increase the anticoagulant activities of Ardeparin.Experimental
ProquazoneProquazone may increase the anticoagulant activities of Ardeparin.Experimental
Protein CArdeparin may increase the anticoagulant activities of Protein C.Approved
Protein S humanArdeparin may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeArdeparin may increase the anticoagulant activities of Protocatechualdehyde.Approved
PTC299PTC299 may increase the anticoagulant activities of Ardeparin.Investigational
QuinestrolQuinestrol may decrease the anticoagulant activities of Ardeparin.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Ardeparin.Investigational
RelcovaptanRelcovaptan may increase the anticoagulant activities of Ardeparin.Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Ardeparin.Approved, Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Ardeparin.Approved, Investigational
ReviparinArdeparin may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Ardeparin.Approved
RivaroxabanArdeparin may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Ardeparin.Approved, Investigational
SacubitrilArdeparin may increase the hyperkalemic activities of Sacubitril.Approved
SalicylamideSalicylamide may increase the anticoagulant activities of Ardeparin.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Ardeparin.Approved
SaprisartanArdeparin may increase the hyperkalemic activities of Saprisartan.Experimental
SaralasinArdeparin may increase the hyperkalemic activities of Saralasin.Investigational
SarpogrelateSarpogrelate may increase the anticoagulant activities of Ardeparin.Investigational
SaruplaseSaruplase may increase the anticoagulant activities of Ardeparin.Experimental
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Ardeparin.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Ardeparin.Approved
SemapimodSemapimod may increase the anticoagulant activities of Ardeparin.Investigational
SeratrodastSeratrodast may increase the anticoagulant activities of Ardeparin.Approved
SerrapeptaseSerrapeptase may increase the anticoagulant activities of Ardeparin.Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Ardeparin.Approved, Vet Approved
SpironolactoneArdeparin may increase the hyperkalemic activities of Spironolactone.Approved
SRT501SRT501 may increase the anticoagulant activities of Ardeparin.Investigational
StreptokinaseStreptokinase may increase the anticoagulant activities of Ardeparin.Approved, Investigational
SugammadexSugammadex may increase the anticoagulant activities of Ardeparin.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Ardeparin.Approved
SulindacSulindac may increase the anticoagulant activities of Ardeparin.Approved, Investigational
SulodexideArdeparin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the anticoagulant activities of Ardeparin.Experimental
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Ardeparin.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Ardeparin.Approved
TarenflurbilTarenflurbil may increase the anticoagulant activities of Ardeparin.Investigational
TasosartanArdeparin may increase the hyperkalemic activities of Tasosartan.Approved
TelmisartanArdeparin may increase the hyperkalemic activities of Telmisartan.Approved, Investigational
TenecteplaseTenecteplase may increase the anticoagulant activities of Ardeparin.Approved
TenidapTenidap may increase the anticoagulant activities of Ardeparin.Experimental
TenoxicamTenoxicam may increase the anticoagulant activities of Ardeparin.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Ardeparin.Vet Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Ardeparin.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Ardeparin.Investigational
Testosterone cypionateThe therapeutic efficacy of Ardeparin can be increased when used in combination with Testosterone cypionate.Approved
Testosterone enanthateThe therapeutic efficacy of Ardeparin can be increased when used in combination with Testosterone enanthate.Approved
Testosterone undecanoateThe therapeutic efficacy of Ardeparin can be increased when used in combination with Testosterone undecanoate.Approved, Investigational
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Ardeparin.Approved
TiboloneTibolone may increase the anticoagulant activities of Ardeparin.Approved, Investigational
TicagrelorTicagrelor may increase the anticoagulant activities of Ardeparin.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Ardeparin.Approved
TinoridineTinoridine may increase the anticoagulant activities of Ardeparin.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Ardeparin.Approved
TioclomarolTioclomarol may increase the anticoagulant activities of Ardeparin.Experimental
TipranavirTipranavir may increase the anticoagulant activities of Ardeparin.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Ardeparin.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Ardeparin.Approved, Investigational
TolmetinTolmetin may increase the anticoagulant activities of Ardeparin.Approved
TositumomabThe risk or severity of adverse effects can be increased when Ardeparin is combined with Tositumomab.Approved, Investigational
TranilastTranilast may increase the anticoagulant activities of Ardeparin.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Ardeparin.Approved
TreprostinilTreprostinil may increase the anticoagulant activities of Ardeparin.Approved, Investigational
TriamtereneArdeparin may increase the hyperkalemic activities of Triamterene.Approved
TribenosideTribenoside may increase the anticoagulant activities of Ardeparin.Experimental
TriflusalTriflusal may increase the anticoagulant activities of Ardeparin.Approved, Investigational
TriptolideTriptolide may increase the anticoagulant activities of Ardeparin.Investigational
Trolamine salicylateTrolamine salicylate may increase the anticoagulant activities of Ardeparin.Approved
TroxerutinArdeparin may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseUrokinase may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ValsartanArdeparin may increase the hyperkalemic activities of Valsartan.Approved, Investigational
Vitamin EVitamin E may increase the anticoagulant activities of Ardeparin.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Ardeparin.Approved
WarfarinArdeparin may increase the anticoagulant activities of Warfarin.Approved
XimelagatranArdeparin may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Ardeparin.Approved, Investigational
ZeranolZeranol may decrease the anticoagulant activities of Ardeparin.Vet Approved
ZileutonZileuton may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the anticoagulant activities of Ardeparin.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Drug
D02980
PubChem Substance
46505194
Therapeutic Targets Database
DAP000428
PharmGKB
PA164754878
Drugs.com
Drugs.com Drug Page
Wikipedia
Ardeparin
MSDS
Download (65.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceAltered Heparin Response / Cardiopulmonary Bypass1
2CompletedPreventionVenous Thromboembolism1
2TerminatedPreventionThrombosis Prophylaxis (Risk of Thrombosis Due to Central Venous Line (CVL)1
2WithdrawnTreatmentDiabetes, Diabetes Mellitus Type 11
3CompletedPreventionCancers / Venous Thromboembolism1
3CompletedPreventionVenous Thromboembolism5
3CompletedTreatmentDeep Vein Thrombosis (DVT)1
3RecruitingPreventionCatheter-Related Infections / Kidney Failure,Chronic1
3TerminatedPreventionVenous Thromboembolism1
4RecruitingTreatmentInfertilities1
Not AvailableRecruitingNot AvailableIntra Operative Bleeding, Blood Salvage1

Pharmacoeconomics

Manufacturers
  • Wyeth ayerst laboratories
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilitySolubleNot Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Serine-type endopeptidase inhibitor activity
Specific Function
Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa. Its inhibitory a...
Gene Name
SERPINC1
Uniprot ID
P01008
Uniprot Name
Antithrombin-III
Molecular Weight
52601.935 Da
References
  1. Mousa SA: The low molecular weight heparin, tinzaparin, in thrombosis and beyond. Cardiovasc Drug Rev. 2002 Fall;20(3):199-216. [PubMed:12397367]
  2. Lin P, Sinha U, Betz A: Antithrombin binding of low molecular weight heparins and inhibition of factor Xa. Biochim Biophys Acta. 2001 Apr 3;1526(1):105-13. [PubMed:11287128]
  3. Shaughnessy SG, Young E, Deschamps P, Hirsh J: The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood. 1995 Aug 15;86(4):1368-73. [PubMed:7632944]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Serine-type endopeptidase inhibitor activity
Specific Function
Thrombin inhibitor activated by the glycosaminoglycans, heparin or dermatan sulfate. In the presence of the latter, HC-II becomes the predominant thrombin inhibitor in place of antithrombin III (AT...
Gene Name
SERPIND1
Uniprot ID
P05546
Uniprot Name
Heparin cofactor 2
Molecular Weight
57070.16 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Mousa SA: The low molecular weight heparin, tinzaparin, in thrombosis and beyond. Cardiovasc Drug Rev. 2002 Fall;20(3):199-216. [PubMed:12397367]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on June 13, 2005 07:24 / Updated on May 01, 2018 22:10